Andhra Pradesh CM unveils Bharat Biotech arm Lumpy Skin Disease vaccine

BIOLUMPIVAXIN which is CDSCO approved, is the safest, Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine, which will help in disease surveillance to protect livestock from Lumpy Skin disease (LSD).

Launching the lumpy skin disease vaccine BIOLUMPIVAXIN, Shri N. Chandrababu Naidu, Hon’ble Chief Minister of Andhra Pradesh, applauded Biovet for the development, and commercialisation of this unique livestock vaccine. The Chief Minister remarked, it is heartening to note the availability of world class made in India vaccine. He emphasised that all viable measures should be taken earnestly to ensure the effective rollout of the vaccine, which not only can contribute to the state’s targeted 20% livestock growth trajectory but also promote the long-term sustainability of the dairy industry.

Expressing gratitude to the Hon’ble Chief Minister Shri. N. Chandrababu Naidu for launching the vaccine and describing the launch of the DIVA Marker LSD vaccine as an important step toward eradicating Lumpy disease, Dr. Krishna Ella, Founder, Biovet, and Executive Chairman of Bharat Biotech, said, 'We are truly honoured. Livestock, alongside our human resources, represents one of the nation’s greatest assets, contributing significantly to our economy and overall prosperity. We carry a deep responsibility to protect this sector, ensure the well-being of the dairy industry, and advance the nation's Atmanirbhar Bharat vision.

BIOLUMPIVAXIN is a novel indigenous live-attenuated marker vaccine developed using the LSD virus/Ranchi/2019 vaccine strain from Indian Council of Agriculture Research-National Research Centre on Equines (ICAR-NRCE), Hisar, in collaboration with Biovet.

The quality, safety, and efficacy of BIOLUMPIVAXIN have been extensively tested at Indian Council of Agriculture Research-Indian Veterinary Research Institute (IVRI) and the Indian Council of Agriculture Research-National Research Centre on Equines (ICAR-NRCE) ensuring it meets the highest global standards. The vaccine also enables serological differentiation between naturally infected and vaccinated animals with the DIVA concept.

This LSD vaccine is a single vaccination regimen given once in a year to cattle and buffaloes of all ages. The presentation is in multi dose vials from 25 doses up to a maximum of 100 doses per vial and the vaccine is stable at 2-8° C storage temperature.

Biovet can produce 500 million doses of the vaccine from its production facilities in Bengaluru, ensuring sustainable supplies.

According to national statistics by the animal husbandry, dairy ministry, there have been two major outbreaks of LSD in India, the first in 2019 and the second in 2022. During these outbreaks approximately 200,000 cattle have died, and millions more cattle have lost their milk production capabilities due to Lumpy Skin Disease (LSD).

When a livestock contracts Lumpy Skin Disease (LSD), it suffers from high fever and painful skin nodules that can prove fatal and contaminate milk production. The infection drastically reduces milk yield, posing a serious threat to large-scale dairies and disrupting the broader milk supply chain.

The Ministry of Animal Husbandry and Dairying, Fisheries, the livestock sector has grown around 10% in the nine years and contributed to total agriculture and allied sector to over 30% from 24.36%.

The dairy industry is a vital pillar of India’s economy, contributing significantly to the country’s GDP and providing a reliable source of daily income to hundreds of millions of farmers, especially women, in rural areas. The introduction of preventive vaccines like BIOLUMPIVAXIN®️ will have a transformative effect on every village and district, ensuring the health of cattle and the continued growth and resilience of the dairy sector.

BIOLUMPIVAXIN, is provided in freeze-dried form with stabilizing agents for long-term stability. Diluent for the reconstitution of freeze-dried vaccine is provided separately. Each vaccine dose contains NLT log10 3.5 /mL. It is a single vaccination regimen given once in a year to cattle and buffaloes above 3 months of age.

The presentation is in multi dose vials from 25 doses up to a maximum of 100 doses per vial and the vaccine is stable at 2-80 C storage temperature.

Dose/Route: 1.0 mL of the reconstituted volume to be inoculated by subcutaneous (S/C) route of injection.

Preclinical studies: Vaccine has been demonstrated for the absence of reversion to virulence, safety, immunogenicity, protective efficacy and superiority of in cattle by conducting vaccination - challenge experiments under controlled conditions in BSL3 animal facility.

Clinical trials/ field studies: Thousands of cattle/buffaloes were vaccinated under field conditions by Biovet and Indian council of agriculture research (ICAR) and vaccine found to be safe and efficacious. Also, it is found to be safe in all the groups of animals including pregnant and lactating cattle and buffaloes apart from breeding bulls.

DIVA marker concept: Post-vaccination seromonitoring helps to differentiate infected animals from that of the vaccinated animals for implementing effective LSD control programs.